{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:22:16Z","timestamp":1791580936056,"version":"4.3.4"},"reference-count":21,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with aggressive B-cell lymphoma and MYC rearrangement at fluorescence in situ hybridization exhibit poor outcome after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). In the last decade, 68 patients with Burkitt lymphoma ([BL] n\u00a0= 46) or high-grade B-cell lymphoma ([HGBCL] single, double, or triple hit; n\u00a0=\u00a022) were treated with a dose-dense, short-term therapy termed \u201cCARMEN regimen\u201d at 5 Italian centers. Forty-six (68%) patients were HIV+. CARMEN included a 36-day induction with sequential, single weekly doses of cyclophosphamide, vincristine, rituximab, methotrexate, etoposide, and doxorubicin plus intrathecal chemotherapy, followed by high-dose-cytarabine\u2013based consolidation. Patients who did not achieve complete remission (CR) after induction received BEAM (carmustina, etoposide, cytarabine, melfalan)-conditioned autologous stem cell transplantation (ASCT) after consolidation. Sixty-one (90%) patients completed induction, and 59 (87%) completed consolidation. Seventeen patients received ASCT. Grade 4 hematological toxicity was common but did not cause treatment discontinuation; grade 4 nonhematological toxicity was recorded in 11 (16%) patients, with grade 4 infections in 6 (9%). Six (9%) patients died of toxicity (sepsis in 4, COVID-19, acute respiratory distress syndrome). CR rate after the whole treatment was 73% (95% confidence interval [CI], 55% to 91%) for patients with HGBCL and 78% (95% CI, 66% to 90%) for patients with BL. At a median follow-up of 65 (interquartile range, 40-109) months, 48 patients remain event free, with a 5-year progression-free survival of 63% (95% CI, 58% to 68%) for HGBCL and 72% (95% CI, 71% to 73%) for BL, with a 5-year overall survival (OS) of 63% (95% CI, 58% to 68%) and 76% (95% CI, 75% to 77%), respectively. HIV seropositivity did not have a detrimental effect on outcome. This retrospective study shows that CARMEN is a safe and active regimen both in HIV-negative and -positive patients with MYC-rearranged lymphomas. Encouraging survival figures, attained with a single dose of doxorubicin and cyclophosphamide, deserve further investigation in HGBCL and other aggressive lymphomas.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007475","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T20:55:17Z","timestamp":1652820917000},"page":"5811-5820","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9606-6124","authenticated-orcid":false,"given":"Andr\u00e9s J. M.","family":"Ferreri","sequence":"first","affiliation":[{"name":"1Lymphoma Unit, Department of Onco-Hematology, IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico) San Raffaele Scientific Institute, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Angelillo","sequence":"additional","affiliation":[{"name":"1Lymphoma Unit, Department of Onco-Hematology, IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico) San Raffaele Scientific Institute, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Erbella","sequence":"additional","affiliation":[{"name":"1Lymphoma Unit, Department of Onco-Hematology, IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico) San Raffaele Scientific Institute, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0031-3237","authenticated-orcid":false,"given":"Chiara","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Ospedali Civili di Brescia, Brescia; Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Verga","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Azienda Ospedaliera San Gerardo, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arben","family":"Lleshi","sequence":"additional","affiliation":[{"name":"4Division of Medical Oncology and Immune-related tumors, IRCCS Centro di Riferimento Oncologico (CRO), Aviano (Pordenone), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardino","family":"Allione","sequence":"additional","affiliation":[{"name":"5A.O. Citt\u00e0 della Salute e della Scienza - Le Molinette, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurilio","family":"Ponzoni","sequence":"additional","affiliation":[{"name":"6Pathology Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy"},{"name":"7Vita-Salute San Raffaele University, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Facchetti","sequence":"additional","affiliation":[{"name":"8Pathology Unit, Ospedali Civili di Brescia, Brescia; Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pagani","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Ospedali Civili di Brescia, Brescia; Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Foppoli","sequence":"additional","affiliation":[{"name":"1Lymphoma Unit, Department of Onco-Hematology, IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico) San Raffaele Scientific Institute, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Pecciarini","sequence":"additional","affiliation":[{"name":"6Pathology Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Sassone","sequence":"additional","affiliation":[{"name":"1Lymphoma Unit, Department of Onco-Hematology, IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico) San Raffaele Scientific Institute, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Steffanoni","sequence":"additional","affiliation":[{"name":"1Lymphoma Unit, Department of Onco-Hematology, IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico) San Raffaele Scientific Institute, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Flospergher","sequence":"additional","affiliation":[{"name":"1Lymphoma Unit, Department of Onco-Hematology, IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico) San Raffaele Scientific Institute, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rossi","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Ospedali Civili di Brescia, Brescia; Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Spina","sequence":"additional","affiliation":[{"name":"4Division of Medical Oncology and Immune-related tumors, IRCCS Centro di Riferimento Oncologico (CRO), Aviano (Pordenone), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Re","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Ospedali Civili di Brescia, Brescia; Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2022111116255842800_bib1","first-page":"335","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Kluin","year":"2017"},{"key":"2022111116255842800_bib2","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Kluin","year":"2008"},{"issue":"6","key":"2022111116255842800_bib3","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Br J Haematol"},{"issue":"3","key":"2022111116255842800_bib4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ajh.26068","article-title":"First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study","volume":"96","author":"Laude","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"2022111116255842800_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cncr.23522","article-title":"High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients","volume":"113","author":"Oriol","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"2022111116255842800_bib6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2015-01-623900","article-title":"AMC 048: modified CODOX-M\/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma","volume":"126","author":"Noy","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2022111116255842800_bib7","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol"},{"issue":"1","key":"2022111116255842800_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bjh.17188","article-title":"A\u00a0dose-dense short-term therapy for human immunodeficiency virus\/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the \u201cCARMEN\u201d phase II trial","volume":"192","author":"Ferreri","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"2022111116255842800_bib9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.12020","article-title":"Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma","volume":"159","author":"Ferreri","year":"2012","journal-title":"Br J Haematol"},{"issue":"3","key":"2022111116255842800_bib10","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"issue":"5","key":"2022111116255842800_bib11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2022111116255842800_bib12","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2141.2004.05141.x","article-title":"High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt\u2019s lymphoma in adults","volume":"126","author":"Di Nicola","year":"2004","journal-title":"Br J Haematol"},{"issue":"4","key":"2022111116255842800_bib13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/PAS.0000000000000147","article-title":"Clinical significance of MYC expression and\/or \u201chigh-grade\u201d morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study","volume":"38","author":"Cook","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"22","key":"2022111116255842800_bib14","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.20.00303","article-title":"Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma","volume":"38","author":"Roschewski","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2022111116255842800_bib15","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1182\/bloodadvances.2021004458","article-title":"HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis","volume":"5","author":"Alderuccio","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2022111116255842800_bib16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2020006926","article-title":"Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers","volume":"137","author":"Evens","year":"2021","journal-title":"Blood"},{"issue":"17","key":"2022111116255842800_bib17","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"issue":"28","key":"2022111116255842800_bib18","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2022111116255842800_bib19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/bjh.12901","article-title":"\u2018Double-Hit\u2019 cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients","volume":"166","author":"Landsburg","year":"2014","journal-title":"Br J Haematol"},{"issue":"24","key":"2022111116255842800_bib20","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1002\/cncr.28899","article-title":"MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches","volume":"120","author":"Petrich","year":"2014","journal-title":"Cancer"},{"issue":"10","key":"2022111116255842800_bib21","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1200\/JCO.20.03288","article-title":"Burkitt Lymphoma International Prognostic Index","volume":"39","author":"Olszewski","year":"2021","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/22\/5811\/1929795\/blooda_adv-2022-007475-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/22\/5811\/1929795\/blooda_adv-2022-007475-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T16:27:06Z","timestamp":1668184026000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/22\/5811\/485287\/Safety-and-efficacy-of-a-dose-dense-short-term"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":21,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2022,11,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007475","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]}}}